InvestorsHub Logo
Followers 8
Posts 126
Boards Moderated 0
Alias Born 11/10/2022

Re: DewDiligence post# 7238

Thursday, 05/02/2024 5:54:37 PM

Thursday, May 02, 2024 5:54:37 PM

Post# of 7950
Evolus reports May 7th after close
Estim Rev: $57M, loss of 8 cents/share.
Q4 2023 Rev: $60M COGS: $19M
Key items: cash burn, interest on debt, cash balance, year on year revenue growth, QoQ revenue change.

Revance reports May 9th after close
Q4 2023: RHA: $34.5M, Daxi: $24M
Key items: RHA/Daxi Revenue growth YoY and QoQ, cash burn, cash balance, GMs, Daxxify vial unit growth QoQ, and CD launch progress and expense management.

Compare to Abbvie's Botox/filler sales for same quarters.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News